Immunotoxins
"A Bivalent Disulfide-Stabilized Fv with Improved Antigen Binding to erbB2."
Published in Cancer Weekly, October 5th, 1998
According to the authors' abstract of an article published in Journal of Molecular Biology, "We have used protein engineering to generate a stable bivalent Fv molecule of the anti-erbB2 monoclonal antibody e23. The V-H and V-L domains of the Fv are linked to each other by a disulfide bond and the two Fvs are connected by a flexible 15 amino acid residue (Gly(4)-Ser)(3) linker. The e23 (dsFv)(2) molecule is fused to a truncated form of Pseudomonas exotoxin to generate a bivalent disulfide-stabilized, (dsFv)(2), immunotoxin. The immunotoxin was expressed in Escherichia coli, refolded in vitro and purified to about 95% purity. Binding studies demonstrated that the (dsFv)(2)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (1998-10-05)
More Articles from Cancer Weekly
- Cancer Gene Therapy
Angiogenesis-Dependent Tumor Growth Can Be Suppressed In a Murine Model - AIDS Cancer
Seeds of AIDS Lymphoma Planted In Early Infection - Cancer Gene Therapy
p53 Gene Therapy Shows Promise Against Pancreatic Cancer - Cancer Immunotherapy
Combination Antibody/Cytokine Therapy Shows In Vivo Potential - Cancer Immunotherapy
Combination Chemotherapy/Immunotherapy Was Promising in Pilot Study - Cancer Immunotherapy
Immune Responses Elicited in IL-2 Gene Therapy Trial of Neuroblastoma - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
